Inclusion Criteria:

- Histological evidence of prostate adenocarcinoma

- Metastatic disease, either measurable (lymph nodes, hepatic lesion, pulmonary lesions
with longest diameter > or = 1 cm on spiral scan), or non measurable (bone
metastasis)

- Patients must:

- Have received hormonal therapy via surgical or chemical castration (LH-RH
agonist) with or without anti-androgens. Anti-androgen withdrawal is recommended
before inclusion, with an off-treatment period of at least 4 weeks. LH-RH
agonist treatment must be continued.

- Have a relapse or disease refractory to hormonal treatment (defined by a
testosterone level < 0.5 µg/ml)

- Have neuroendocrine progression defined, whatever the PSA level, as:

- NSE and/or Chromogranin A > 1.5 x upper limit of normal (ULN) with or
without visceral metastases (liver, lung, lymph node)

- No increase of NSE or Chromogranin A, but visceral metastases (either
hepatic, pleuro-pulmonary, or nodal) with cytological or histological
confirmation of the presence of an undifferentiated or neuro-endocrine
component of prostatic origin

- Prior treatment by radiotherapy is allowed but radiation therapy must have been
completed for at least 4 weeks before inclusion and irradiated areas must not
represent more than 25% of marrow reserves

- Prior treatment by estramustine is allowed but must have been stopped at least 4
weeks before inclusion

- Age> or = 18 years

- Life expectancy> or = 3 months

- Karnofsky index> or = 50%

- Adequate haematological function: neutrophils> or = 1.5 G/l, platelets> or = 100 G/l,
haemoglobin> or = 8 g/dl. Use of erythropoietin is allowed.

- Adequate liver function: bilirubin level within the institution's normal range, AST
and ALT< or = 1.5 ULN

- Adequate renal function: creatinine clearance> or = 40 ml/min (Gault and Cockroft
method)

- Signed written informed consent.

Exclusion Criteria:

- Patients having no> 1.5 x ULN increase of at least one neuro-endocrine marker (NSE or
chromogranin A) and no cytological or histological (undifferentiated or
neuro-endocrine type) evidence of visceral metastasis (hepatic, pleuro-pulmonary, or
nodal)

- History of other malignancies, other than curatively treated basal cell skin
carcinoma or any other curatively treated cancer with no sign of recurrence within 5
years

- Symptomatically uncontrolled brain metastasis

- Interstitial radiation therapy (using strontium or samarium) within the previous 3
months

- Prior treatment with platinum salts or etoposide. Other chemotherapy regimens are
allowed provided that the last dose has been administered> or = 4 weeks prior to
inclusion.

- Concomitant treatment with other anti-cancer drugs, except corticoid or LH-RH agonist
injections

- Peripheral neuropathy> or = 2 (NCI-CTCAE)

- Uncontrolled progressive thrombo-embolic disease

- Uncontrolled infection

- Medical history of acute myocardial infection or uncontrolled angina pectoris, or
hypertension or uncontrolled arrythmia

- Inclusion in another clinical trial

- Impaired follow-up for social, geographical, familial or psychological reasons

- Any other unstable disease.